BURLINGTON, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2022 financial results on Thursday, February 23, 2023, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook.
Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor.
About LeMaitre
LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre.com.
LeMaitre and the LeMaitre logo are registered trademarks of LeMaitre Vascular, Inc.
Contact:
Sandra Millar
LeMaitre Vascular, Inc.
+1-781-425-1686
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$94.90 |
Daily Change: | 2.15 2.32 |
Daily Volume: | 196,520 |
Market Cap: | US$2.130B |
December 16, 2024 October 31, 2024 August 01, 2024 May 02, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load